Imatinib-Induced Sweet Syndrome in a Patient With Chronic Myeloid Leukemia

Abstract

Background: Imatinib mesylate has become one of the main chemotherapeutic agents currently used to treat patients with chronic myeloid leukemia (CML). Although cutaneous reactions to this drug have been documented before, this is the first time that Sweet syndrome has been reported with its use. Observations:We report a case of Sweet syndrome secondary to the administration of imatinib to treat CML. On 2 separate occasions, a 53-year-old African Ameri-can woman with CML developed neutrophilic dermatosis consistent with Sweet syndrome after chemotherapy with imatinib.

Oral and cutaneous lichenoid reaction secondary to imatinib: report of two cases

“…Several cutaneous side‐effects associated with imatinib have been reported. Treatment with imatinib has been associated with acute generalized exanthematous pustulosis, 4,5 pityriasis rosea‐like eruption, 6 Stevens–Johnson syndrome, 7 Sweet syndrome, 8 follicular mucinosis, 9 mycosis fungoides‐like reaction, 10 purpuric vasculitis, 11 and repigmentation of gray hair 12 . Only four case reports of lichenoid drug reaction associated with imatinib have been published.…”

Imatinib, dasatinib and nilotinib: a review of adverse cutaneous reactions with emphasis on our clinical experience

“…Other neutrophilic dermatoses have been described after imatinib therapy, such as Sweet syndrome (two patients), neutrophilic eccrine hidradenitis (one patient), recurrent neutrophilic panniculitis (one patient) and erythema nodosum (two patients) …”

Sweet's syndrome with hematologic disorders: a review and reappraisal

“…A patient has been described with Sweet's syndrome occurring after treatment with imatinib, a tyrosine kinase inhibitor that targets the bcr‐abl fusion gene in the Philadelphia chromosome. Causality was postulated, with no mechanism of action hypothesized 32 Chronic lymphocytic leukemia (CLL)/Hairy cell leukemia (HCL).…”